{"id":"car-t","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAR-T cell therapy involves extracting a patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that targets tumor-associated antigens, and reinfusing the engineered cells to attack and eliminate malignant cells. The CAR combines an extracellular antigen-binding domain with intracellular signaling domains to enable T cell activation and proliferation upon encountering target cancer cells. This approach harnesses the patient's own immune system for personalized cancer treatment.","oneSentence":"CAR-T cells are engineered T lymphocytes that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:57.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/CAR_T_cell","title":"CAR T cell","extract":"In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor."},"indications":{"approved":[{"name":"Hematologic malignancies (specific indication under Phase 3 evaluation at Peking University People's Hospital)"}]},"trialDetails":[{"nctId":"NCT07496073","phase":"PHASE1","title":"A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-20","conditions":"Brain (Nervous System) Cancers","enrollment":30},{"nctId":"NCT06038474","phase":"PHASE2","title":"Descartes-08 for Patients With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2024-02-12","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":6},{"nctId":"NCT07488923","phase":"PHASE1","title":"A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs","status":"NOT_YET_RECRUITING","sponsor":"Moonlight Bio, Inc","startDate":"2026-05","conditions":"Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC)","enrollment":110},{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74},{"nctId":"NCT06579469","phase":"","title":"Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-01-20","conditions":"B-ALL, Hematologic Malignancy, Solid Tumor","enrollment":100},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT07489287","phase":"PHASE1","title":"GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-06-15","conditions":"Platinum-resistant Ovarian Cancer","enrollment":18},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT02830724","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":"Pancreatic Cancer, Renal Cell Cancer, Breast Cancer","enrollment":124},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT05753501","phase":"PHASE1","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-09","conditions":"Hematologic Cancer","enrollment":135},{"nctId":"NCT01087294","phase":"PHASE1","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-04","conditions":"Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins","enrollment":85},{"nctId":"NCT07297667","phase":"PHASE1","title":"GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-01","conditions":"Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT05674175","phase":"PHASE1, PHASE2","title":"Co-administration of CART22-65s and huCART19 for B-ALL","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2023-01-25","conditions":"B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma","enrollment":93},{"nctId":"NCT05621291","phase":"NA","title":"A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"B-All, Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT06179888","phase":"PHASE2","title":"Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-27","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Acute Lymphoblastic Leukemia, B-All","enrollment":20},{"nctId":"NCT07250087","phase":"PHASE1","title":"Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-21","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT07493044","phase":"PHASE1","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","startDate":"2026-03-20","conditions":"Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT07341191","phase":"PHASE2","title":"Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-31","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT07371403","phase":"NA","title":"MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"King Hussein Cancer Center","startDate":"2026-02","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Refractory","enrollment":12},{"nctId":"NCT06847269","phase":"PHASE2","title":"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-21","conditions":"Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT05826535","phase":"PHASE1, PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":"Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":270},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT06482905","phase":"PHASE1","title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","status":"RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2024-09-04","conditions":"High-grade Glioma, WHO Grade Ⅳ Glioma","enrollment":52},{"nctId":"NCT07223021","phase":"PHASE3","title":"A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-20","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":130},{"nctId":"NCT05514327","phase":"NA","title":"A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-09-01","conditions":"Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy","enrollment":20},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":"Relapsed/Refractory CD19-positive B-ALL","enrollment":6},{"nctId":"NCT02315612","phase":"PHASE1","title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"NHL, Large Cell Lymphoma, Follicular Lymphoma","enrollment":134},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT07250269","phase":"PHASE1","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2025-10-29","conditions":"Relapsed/Refractory AL Amyloidosis","enrollment":9},{"nctId":"NCT07490951","phase":"NA","title":"Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","startDate":"2026-03-22","conditions":"Autoimmune Diseases","enrollment":20},{"nctId":"NCT07489534","phase":"PHASE2","title":"Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-09-29","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT06799247","phase":"PHASE3","title":"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","status":"RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2025-05-06","conditions":"Myasthaenia Gravis","enrollment":100},{"nctId":"NCT05680922","phase":"PHASE1","title":"DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Legend Biotech USA Inc","startDate":"2023-07-26","conditions":"Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung","enrollment":41},{"nctId":"NCT07081646","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-18","conditions":"Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis","enrollment":91},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT07489989","phase":"PHASE2","title":"Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-05-15","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":30},{"nctId":"NCT05003895","phase":"PHASE1","title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":"SLE (Systemic Lupus)","enrollment":3},{"nctId":"NCT07200102","phase":"PHASE1","title":"Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-17","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT07487402","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-03-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT05798117","phase":"PHASE1, PHASE2","title":"An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-28","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis","enrollment":21},{"nctId":"NCT05201781","phase":"PHASE4","title":"A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-09","conditions":"Multiple Myeloma","enrollment":295},{"nctId":"NCT07487597","phase":"EARLY_PHASE1","title":"Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors","status":"RECRUITING","sponsor":"TCRCure Biopharma Ltd.","startDate":"2026-02-28","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT06789081","phase":"EARLY_PHASE1","title":"GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-02-01","conditions":"Alveolar Soft Part Sarcoma","enrollment":1},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT07485504","phase":"PHASE1","title":"Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2026-04-15","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":15},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT07333677","phase":"EARLY_PHASE1","title":"In Vivo CAR-T for Refractory Graves' Disease","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-29","conditions":"Graves' Disease","enrollment":5},{"nctId":"NCT06158139","phase":"PHASE1","title":"Autologous CAR-T Cells Targeting B7-H3 in PDAC","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-07-18","conditions":"Pancreas Cancer, Relapse, Resistant Cancer","enrollment":27},{"nctId":"NCT03827343","phase":"","title":"Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-23","conditions":"Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis","enrollment":500},{"nctId":"NCT06658951","phase":"NA","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"UTC Therapeutics Inc.","startDate":"2025-04-03","conditions":"HER2-positive Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT07481721","phase":"PHASE1","title":"IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma","status":"NOT_YET_RECRUITING","sponsor":"Ming Yang","startDate":"2026-05-01","conditions":"Recurrent Malignant Glioma","enrollment":24},{"nctId":"NCT06375993","phase":"PHASE1","title":"A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Adicet Therapeutics","startDate":"2024-11-10","conditions":"Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc)","enrollment":180},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT06071624","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-02-21","conditions":"Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT07478848","phase":"PHASE1","title":"Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-07","conditions":"Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":14},{"nctId":"NCT07479797","phase":"PHASE3","title":"Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-08","conditions":"Relapsed or Refractory Large B-cell Lymphoma (r/r LBCL)","enrollment":550},{"nctId":"NCT02601313","phase":"PHASE2","title":"Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-11-09","conditions":"Relapsed/Refractory Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT06153251","phase":"PHASE1","title":"A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-23","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":187},{"nctId":"NCT06500273","phase":"PHASE2","title":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","status":"RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2024-06-18","conditions":"Large B-cell Lymphoma","enrollment":250},{"nctId":"NCT07479927","phase":"NA","title":"Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy","status":"RECRUITING","sponsor":"Hospital Universitario La Paz","startDate":"2025-12-19","conditions":"Acute Lymphoblastic Leukemia","enrollment":40},{"nctId":"NCT07413835","phase":"NA","title":"Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2026-03-17","conditions":"Refractory Myasthenia Gravis","enrollment":6},{"nctId":"NCT04889716","phase":"PHASE2","title":"CAR-T Followed by Bispecific Antibodies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-05","conditions":"Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT06068400","phase":"NA","title":"Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-09-21","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":1},{"nctId":"NCT07477912","phase":"PHASE1, PHASE2","title":"Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2025-02-01","conditions":"Multiple Myeloma Refractory","enrollment":30},{"nctId":"NCT07476027","phase":"EARLY_PHASE1","title":"Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-15","conditions":"T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia","enrollment":10},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":440},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT03455972","phase":"PHASE1, PHASE2","title":"Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-02-20","conditions":"Safety and Efficacy","enrollment":43},{"nctId":"NCT05909527","phase":"PHASE1, PHASE2","title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","status":"WITHDRAWN","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-05-01","conditions":"T-Cell Acute Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT07015983","phase":"PHASE2","title":"A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-07-14","conditions":"Lupus Erythematosus, Systemic, Lupus Nephritis","enrollment":89},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT07164560","phase":"PHASE1","title":"Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-04-01","conditions":"Refractory/Recurrent Peripheral T-cell Lymphoma","enrollment":45},{"nctId":"NCT06865664","phase":"PHASE1","title":"FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-22","conditions":"Rhabdomyosarcoma","enrollment":50},{"nctId":"NCT07475182","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","status":"RECRUITING","sponsor":"Hainan Cancer Hospital","startDate":"2025-12-06","conditions":"Advanced Solid Cancers","enrollment":10},{"nctId":"NCT07474051","phase":"","title":"Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials","status":"ENROLLING_BY_INVITATION","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-29","conditions":"B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy","enrollment":178},{"nctId":"NCT06026319","phase":"PHASE1","title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-10-26","conditions":"Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07038447","phase":"PHASE1","title":"A Study of KITE-363 in Participants With Refractory Autoimmune Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2025-07-02","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis","enrollment":52},{"nctId":"NCT07472972","phase":"","title":"Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2025-06-20","conditions":"Lymphoma, Lymphoid Hematological Malignancies","enrollment":50},{"nctId":"NCT06561425","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galapagos NV","startDate":"2022-03-09","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell","enrollment":130},{"nctId":"NCT07137494","phase":"PHASE1","title":"A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-14","conditions":"Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT07473154","phase":"PHASE1, PHASE2","title":"Controlling Hyperactive Immunity With Long-lived Lymphocytes","status":"NOT_YET_RECRUITING","sponsor":"Quell Therapeutics Limited","startDate":"2026-04","conditions":"Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)","enrollment":16},{"nctId":"NCT03590574","phase":"PHASE1, PHASE2","title":"Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma","status":"TERMINATED","sponsor":"Autolus Limited","startDate":"2018-08-30","conditions":"T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT04703686","phase":"PHASE2","title":"Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-30","conditions":"Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma","enrollment":67},{"nctId":"NCT07285694","phase":"PHASE1, PHASE2","title":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","status":"RECRUITING","sponsor":"Arsenal Biosciences, Inc.","startDate":"2026-01-09","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":190},{"nctId":"NCT05024175","phase":"","title":"Long-term Follow-up of Subjects Treated With CAR T Cells","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-08-07","conditions":"Long Term Adverse Effects, CAR-T, Duty to Follow Up","enrollment":45},{"nctId":"NCT06481735","phase":"PHASE1, PHASE2","title":"TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-02-15","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT06186401","phase":"PHASE1","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","status":"RECRUITING","sponsor":"Hideho Okada, MD, PhD","startDate":"2024-04-30","conditions":"EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17588,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anti-CLL1-CD33-NKG2D Bicephali CAR-T cells","CAR-T alone","Chimeric antigen receptor-modified T (CAR-T) cell therapy"],"phase":"phase_3","status":"active","brandName":"CAR-T","genericName":"CAR-T","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAR-T cells are engineered T lymphocytes that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens. Used for Hematologic malignancies (specific indication under Phase 3 evaluation at Peking University People's Hospital).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}